Loading
companiesCompany
Tubulis (Gilead)
German ADC company whose NaPi2b ADC TUB-040 posted a 59% response rate in platinum-resistant ovarian cancer; Gilead agreed to buy it for up to $5B.
Overview
Raised a record €344M Series C (October 2025) after TUB-040 phase 1/2a data at ESMO 2025 (59% ORR in platinum-resistant ovarian cancer; also lung adenocarcinoma). Gilead announced an acquisition at $3.15B upfront plus up to $1.85B milestones, expected to close Q2 2026. Proprietary Tubutecan and P5 conjugation chemistries.
Similar pages
- TrialStudy of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Shares Gilead Sciences (incl. Kite), Antibody-drug conjugate (ADC), Non-small-cell lung cancer.
- TrialStudy of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)
Shares Gilead Sciences (incl. Kite), Antibody-drug conjugate (ADC), Non-small-cell lung cancer.
- TreatmentLuveltamab tazevibulin
Shares Site-specific conjugation & linker chemistry, Antibody-drug conjugate (ADC), Ovarian cancer.
- TechnologyAntibody-oligonucleotide conjugates
Shares Site-specific conjugation & linker chemistry, Antibody-drug conjugate (ADC).
- CompanySutro Biopharma
Shares Site-specific conjugation & linker chemistry, Antibody-drug conjugate (ADC), Ovarian cancer.
- TrialARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)
Shares Site-specific conjugation & linker chemistry, Antibody-drug conjugate (ADC).
- TermDrug-to-antibody ratio (DAR)
Shares Site-specific conjugation & linker chemistry, Antibody-drug conjugate (ADC).
- TrialStudy of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)
Shares Gilead Sciences (incl. Kite), Antibody-drug conjugate (ADC), Non-small-cell lung cancer.
cancers
fronts
technologies
companies
trials
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLCFirst in Human Study of TUB-030 in Patients With Advanced Solid TumorsStudy of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian CancerStudy of TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-small Cell Lung Cancer